These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23092806)

  • 1. Localization of the stem cell markers LGR5 and Nanog in the normal and the cancerous human ovary and their inter-relationship.
    Amsterdam A; Raanan C; Schreiber L; Freyhan O; Schechtman L; Givol D
    Acta Histochem; 2013 May; 115(4):330-8. PubMed ID: 23092806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential localization of LGR5 and Nanog in clusters of colon cancer stem cells.
    Amsterdam A; Raanan C; Schreiber L; Freyhan O; Fabrikant Y; Melzer E; Givol D
    Acta Histochem; 2013 May; 115(4):320-9. PubMed ID: 23098761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer.
    Virant-Klun I; Kenda-Suster N; Smrkolj S
    J Ovarian Res; 2016 Mar; 9():12. PubMed ID: 26940129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD24 and Nanog identify stem cells signature of ovarian epithelium and cysts that may develop to ovarian cancer.
    Schreiber L; Raanan C; Amsterdam A
    Acta Histochem; 2014 Mar; 116(2):399-406. PubMed ID: 24103524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LGR5 and Nanog identify stem cell signature of pancreas beta cells which initiate pancreatic cancer.
    Amsterdam A; Raanan C; Schreiber L; Polin N; Givol D
    Biochem Biophys Res Commun; 2013 Apr; 433(2):157-62. PubMed ID: 23438436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
    Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae.
    Auersperg N
    Int J Gynecol Pathol; 2013 Sep; 32(5):444-53. PubMed ID: 23896717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
    Kenda Suster N; Smrkolj S; Virant-Klun I
    J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
    Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
    Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: (1) "differential localization of LGR5 and Nanog in clusters of colon cancer stem cells" by Amsterdam A, Raanan C, Schreiber L, Freyhan O, Fabrikant Y, Melzer E, Givol D [Acta Histochem. (2012, October 23), pii: S0065-1281(12)00112-2] and (2) "localization of the stem cell markers LGR5 and Nanog in the normal and the cancerous human ovary and their inter-relationship" by Amsterdam A, Raanan C, Schreiber L, Freyhan O, Schechtman L, Givol D [Acta Histochem. (2012, October 20), pii: S0065-1281(12)00113-4].
    Wright N
    Acta Histochem; 2013 Sep; 115(7):770-1. PubMed ID: 23522104
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of multiple biomarkers for the localization and characterization of colon cancer stem cells by indirect immunocytochemistry.
    Amsterdam A; Raanan C; Schreiber L; Freyhan O; Fabrikant Y; Melzer E
    Int J Oncol; 2012 Jul; 41(1):285-91. PubMed ID: 22504585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers.
    Hoei-Hansen CE; Kraggerud SM; Abeler VM; Kaern J; Rajpert-De Meyts E; Lothe RA
    Mol Cancer; 2007 Feb; 6():12. PubMed ID: 17274819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors.
    Parte SC; Batra SK; Kakar SS
    J Ovarian Res; 2018 Aug; 11(1):69. PubMed ID: 30121075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian Cancer Stem Cells: Unraveling a Germline Connection.
    Parte SC; Smolenkov A; Batra SK; Ratajczak MZ; Kakar SS
    Stem Cells Dev; 2017 Dec; 26(24):1781-1803. PubMed ID: 29078734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers.
    Yi BR; Kim TH; Kim YS; Choi KC
    Int J Oncol; 2015 Jan; 46(1):272-80. PubMed ID: 25310727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epiregulin as a marker for the initial steps of ovarian cancer development.
    Amsterdam A; Shezen E; Raanan C; Slilat Y; Ben-Arie A; Prus D; Schreiber L
    Int J Oncol; 2011 Nov; 39(5):1165-72. PubMed ID: 21769422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
    Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of growth hormone secretagogue receptor type 1a, the functional ghrelin receptor, in human ovarian surface epithelium, mullerian duct derivatives, and ovarian tumors.
    Gaytan F; Morales C; Barreiro ML; Jeffery P; Chopin LK; Herington AC; Casanueva FF; Aguilar E; Dieguez C; Tena-Sempere M
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1798-804. PubMed ID: 15585554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer.
    Amsterdam A; Shezen E; Raanan C; Schreiber L; Prus D; Slilat Y; Ben-Arie A; Seger R
    Int J Oncol; 2011 Sep; 39(3):649-56. PubMed ID: 21687944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.